Published October 27, 2026 · Compiled from the S-1/A filed on SEC EDGAR on 2026-10-26 and the Quintarthai IPO calendar. Quoted passages are the filing's own words.

Aspen Neuroscience, Inc. (ASPE) IPO: what the S-1/A filing says

Aspen Neuroscience, Inc. filed an S-1/A with the SEC on 2026-10-26 in connection with its US listing.

In the Quintarthai IPO calendar: status Upcoming, exchange NASDAQ, expected listing date Oct 30, 2026.

Use of proceeds (quoted from the filing)

• “We estimate that the net proceeds to us from this offering will be approximately $134.5 million (or approximately $155.4 million if the underwriters exercise their option to purchase additional shares in full), based on the assumed initial public offering price of $16.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the…”
• “We may also use a portion of the remaining net proceeds and our existing cash, cash equivalents and marketable securities to in-license, acquire, or invest in complementary businesses, technologies, products, or assets.”
• “Based on our current operating plans, we believe that the estimated net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations into the second half of 2028.”

Source: S-1/A on SEC EDGAR · IPO research page: ASPE.

Research and analysis only — not investment advice, not a recommendation to apply or avoid.